The Data Dilemma: How Much, And What Quality Drives AI Outcomes In Biotech?

Recursion and EVQLV are applying similar underlying computational biology tools to affect positive outcomes in biologic drug discovery, but they’re doing it at two very different scales. In this segment from the Bioprocess Online Live event, How Computational Biology Speeds Drug Discovery, Development, Recursion President and COO Tina Larson and EVQLV CEO and Co-Founder Andrew Satz share their approaches to the volume, organization, and quality of data that drive results.